## 결핵 진료지침

42. Chung C, Kim YJ, Jo KW, Shim TS. Safety of latent tuberculosis infection treatment in older patients with immune-mediated inflammatory diseases. Clin Rheumatol 2022;41:889–97.
43. Noh CS, Kim HI, Choi H, Kim Y, Kim CH, Choi JH, et al. Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older. Respir Med 2019;157:52–8.
44. Feng JY, Huang WC, Lin SM, Wang TY, Lee SS, Shu CC, et al. Safety and treatment completion of latent tuberculosis infection treatment in the elderly population-A prospective observational study in Taiwan. Int J Infect Dis 2020;96:550–7.
45. Campbell JR, Trajman A, Cook VJ, Johnston JC, Adjobimey M, Ruslami R, et al. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis 2020;20:318–29.
46. Huang HL, Lee MR, Cheng MH, Lu PL, Huang CK, Sheu CC, et al. Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection. Clin Infect Dis 2021;73:e1064–e71.
47. Gao L, Zhang H, Xin H, Liu J, Pan S, Li X, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J 2018;52.
48. Haas MK, Aiona K, Erlandson KM, Belknap RW. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis. Clin Infect Dis 2021;73:e3459–e67.
49. Huang HL, Huang WC, Lin KD, Liu SS, Lee MR, Cheng MH, et al. Completion Rate and Safety of Programmatic Screening and Treatment for Latent Tuberculosis Infection in Elderly Patients With Poorly Controlled Diabetic Mellitus: A Prospective Multicenter Study. Clin Infect Dis 2021;73:e1252–e60.
50. Sadowski C, Belknap R, Holland DP, Moro RN, Chen MP, Wright A, et al.

<PAGE>351 VIII. 잠복결핵감염